Amy Schulman is a managing partner at Polaris Partners, which she joined in 2014, focusing on healthcare companies and early stage biotech start-ups. In 2017 she co-founded the Polaris Innovation Fund, which she continues to manage alongside her role as a managing partner of the Polaris main funds. Before Polaris she worked at Pfizer as general counsel and then as president of both Pfizer Nutrition and Pfizer Consumer Healthcare, practised law as a partner at DLA Piper and began her career in litigation at Cleary Gottlieb Steen & Hamilton in 1991. She chairs the board of Alnylam Pharmaceuticals, sits on the board of Elevance Health, and joined Harvard Business School's faculty as a Senior Lecturer in July 2014.
Education
Wesleyan University (Phi Beta Kappa graduate)
Yale Law School
Previous Experience
General Counsel, Pfizer
President, Pfizer Nutrition
President, Pfizer Consumer Healthcare
Partner, DLA Piper
Litigation attorney, Cleary Gottlieb Steen & Hamilton (from 1991)
Co-founder and Executive Chair of the Board, Lyndra Therapeutics
Notable Investments
KallyopeQurAlisLarkspur
Board Seats
Alnylam Pharmaceuticals
Elevance Health
Kallyope
QurAlis
Larkspur
Action Against Hunger
Mount Sinai Hospital
California Institute of Technology
Career Timeline
1991
Began her career in litigation with Cleary Gottlieb Steen & Hamilton.
2014
Joined Polaris Partners.
2014
Joined Harvard Business School's faculty as a Senior Lecturer in July.
2017
Co-founded the Polaris Innovation Fund, which she continues to manage.
2023
Named as Lyndra Therapeutics' Co-Founder and Executive Chair of the Board in a company announcement.
null
Serves on Singapore's Human Health and Potential International Advisory Council and Singapore's Research, Innovation and Enterprise Council.